000153146 001__ 153146
000153146 005__ 20251017144651.0
000153146 0247_ $$2doi$$a10.1007/s12094-025-03896-z
000153146 0248_ $$2sideral$$a143577
000153146 037__ $$aART-2025-143577
000153146 041__ $$aeng
000153146 100__ $$aMoreno, F.
000153146 245__ $$aCDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions
000153146 260__ $$c2025
000153146 5203_ $$aPurpose
To assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.
Methods
A survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.
Results
Fifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.
Conclusions
Use of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.
000153146 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000153146 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000153146 700__ $$aIranzo, V.
000153146 700__ $$aÁlvarez, I.
000153146 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza
000153146 700__ $$aChacón, J. I.
000153146 700__ $$aGavilá, J.
000153146 700__ $$aMartín, M.
000153146 700__ $$aSánchez Rovira, P.
000153146 700__ $$aGratal, P.
000153146 700__ $$aFernández González, M. J.
000153146 700__ $$aLópez, R.
000153146 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000153146 773__ $$g(2025), [8 pp.]$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X
000153146 8564_ $$s742361$$uhttps://zaguan.unizar.es/record/153146/files/texto_completo.pdf$$yVersión publicada
000153146 8564_ $$s1998415$$uhttps://zaguan.unizar.es/record/153146/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000153146 909CO $$ooai:zaguan.unizar.es:153146$$particulos$$pdriver
000153146 951__ $$a2025-10-17-14:36:40
000153146 980__ $$aARTICLE